liver diseases in patients with hiv infections
TRANSCRIPT
![Page 1: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/1.jpg)
Liver diseases in patients with HIV infection Aung Zayar Paing
![Page 2: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/2.jpg)
Introduction
� Abnormal liver function tests can be seen frequently in HIV patients. (prevalence as high as 30%)
� Liver disease is the second commonest cause of mortality in HIV patients.
� Hepatitis virus coinfections represent the most significant cause of liver disease in HIV patients.
� Some other conditions also play their role to cause liver injury in HIV patients.
![Page 3: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/3.jpg)
Lancet 2011; 377: 1198–1209
![Page 4: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/4.jpg)
AIDS Rev. 2013; 15:25-31
![Page 5: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/5.jpg)
Lancet 2011; 377: 1198–1209
![Page 6: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/6.jpg)
Different causes of hepatitis in HIV infected patients
![Page 7: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/7.jpg)
HAIVN M2-08-Hepatic Toxicity in Patients Taking ARVs-EN
![Page 8: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/8.jpg)
HAIVN M2-08-Hepatic Toxicity in Patients Taking ARVs-EN
![Page 9: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/9.jpg)
Hepatitis Coinfections
![Page 10: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/10.jpg)
AIDS Rev. 2013; 15:25-31
![Page 11: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/11.jpg)
HBV coinfection
� ARVs like Tenofovir (TDF), Lamivudine (3TC) and Emtricitabine (FTC) are active against HIV as well as HBV.
� WHO guideline 2013 recommends to start ART for HIV-HBV coinfected patients with evidence of severe chronic liver disease.
� US DHHS guideline advises to start ART for all patients who need anti-HBV treatment.
![Page 12: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/12.jpg)
Hepatic flare up after HAART in HBV coinfected patients
� Some patients with HIV-HBV coinfection experience hepatic flare up having high ALT levels.
� Like IRIS associated with OIs, high antigen burden (high HBV DNA level) (ID 2009:199, Crane et al. http://jid.oxfordjournals.org/)
![Page 13: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/13.jpg)
ALT and HBV DNA values in HF and non-HF subjects over 1st 12 weeks after HAART initiation. x-axis: Weeks after HAART initiation. y-axis 1: HBV DNA log 10 c/ml. y-axis 2: ALT IU/L. Avihingsanon et al. AIDS Research and Therapy 2012 9:6 doi:10.1186/1742-6405-9-6
![Page 14: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/14.jpg)
HCV coinfection
� Nearly 1/3 of HCV patients progress to cirrhosis at a median time of less than 20 years.
� Compared to HCV monoinfected patients, HIV-HCV coinfected patients have 3 times greater risk of progression to cirrhosis or decompensated liver disease.
� Peginterferon + Ribavirin is the mainstay treatment.
� Interferon sparing regimens are possible for some genotypes recently after the introduction of new directly active antiviral (DAA) Sofosbuvir.
![Page 15: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/15.jpg)
AA
SLD
Gui
delin
e
![Page 16: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/16.jpg)
Drug interaction and toxicities
� AZT + RBV - increased risk of anemia
� ddI + RBV – life threatening ddI-associated mitochondrial toxicity including hepatomegaly/steatosis, pancreatitis, and lactic acidosis
� ABC - decreased response to PegIFN/RBV ???
� Other DAAs, Boceprevir and telaprevir interacts significantly with EFV.
![Page 17: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/17.jpg)
Hepatitis E virus infection in HIV patients
� Some studies showed that HIV infected patients have increased susceptibility to hepatitis E virus infection.
� Acute HEV infection can mimic drug induced liver injury.
� HIV patients have risk of chronic HEV infection. (HEV RNA in serum or stools for 6 months or more)
� Myanmar is one of the countries with high prevalence of HEV infection.
![Page 18: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/18.jpg)
Sour
ce: T
he L
ance
t 201
2; 3
79:2
477-
2488
(DO
I:10.
1016
/S0
140-
6736
(11)
6184
9-7)
Source and route of HEV1–4 infection HEV1 and HEV2 are waterborne only, with possible human-to-human transmission, including vertical transmission.
![Page 19: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/19.jpg)
![Page 20: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/20.jpg)
![Page 21: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/21.jpg)
Hepatotoxicity of drugs
![Page 22: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/22.jpg)
HAIVN M2-08-Hepatic Toxicity in Patients Taking ARVs-EN
![Page 23: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/23.jpg)
HAIVN M2-08-Hepatic Toxicity in Patients Taking ARVs-EN
![Page 24: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/24.jpg)
Martin Fisher’s presentation: ICVH 2013
![Page 25: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/25.jpg)
Jour
nal o
f Hep
atol
ogy
2011
vol
. 54
| 77
3–79
4
![Page 26: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/26.jpg)
Martin Fisher’s presentation: ICVH 2013
![Page 27: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/27.jpg)
Hyperbilirubinemia due to some PIs
Liver metabolism of bilirubin and potential mechanisms of interference of atazanavir (ATV) and indinavir (IDV). Uridine diphosphate glucuronosyltransferase 1A1 is the liver enzyme that conjugates the bilirubin. The insertion of an extra dinucleotide (TA) on the promoter gene of the UGT1A1 results in a decreased enzyme activity. Atazanavir and IDV inhibit the UGT1A1, which in turn result in hyperbilirubinemia.
http://www.nature.com/tpj/journal/v6/n4/fig_tab/6500374f6.html
![Page 28: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/28.jpg)
ACTG grading system for hepatotoxicity
Grade 1 Grade 2 Grade 3 Grade 4 ALT* ≤ 2.5 x ULN 2.6 – 5.0 x ULN 5.1-10.0 x ULN 10.0 x ULN
If Grade 1 or 2 hepatotoxicity occurs during NVP lead-‐in dose, lead-‐in dose can extend next 2 weeks (maximum). If ALT sFll raised and < grade 2 stop NVP and start EFV.
![Page 29: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/29.jpg)
Other conditions
![Page 30: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/30.jpg)
Alcoholic hepatitis
� Alcoholism is common in HIV patients and alcoholic hepatitis sometimes complicate HIV treatment.
� Abrupt stopping of alcohol in chronic drinker is dangerous and the patient may suffer from alcohol withdrawal. (mild to sever manifestation like Delirium Tremens)
![Page 31: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/31.jpg)
Signs and symptoms
CCO HIV inPractice
![Page 32: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/32.jpg)
� AST/ALT ratio - usually > 1
� GGT - may be increased (low sensitivity/specificity for alcohol abuse
� Bilirubin may be increased
� INR - raised
� PT - prolonged
![Page 33: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/33.jpg)
Nonalcoholic Fatty Liver Disease (NAFLD)
� NAFLD is the condition caused by accumulation of Triglycerides in hepatocytes associated with obesity, diabetes mellitus and hyperlipidemia.
� Non-alcoholic steatohepatitis is the progressive form of NAFLD.
� 40-70% HIV-HCV coinfected patients are found to have hepatic steatosis.
� The risk is higher in patients taking ddI or d4T
� AST/ALT ration is usually < 1
![Page 34: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/34.jpg)
http://dx.doi.org/10.1155/2013/493413
![Page 35: Liver Diseases in Patients with HIV infections](https://reader035.vdocuments.site/reader035/viewer/2022062514/55a75ae21a28ab79458b4794/html5/thumbnails/35.jpg)
Thank you